Part 1 Validation. The Parties, through the JSC and in accordance with Article 2 (Collaboration Management), will review the data in the Preliminary Validation Data Package to select up to [**] (or more, if mutually agreed by the Parties) such Screened Targets (each, a “Selected Target”) from which the JSC shall determine that all or a subset shall advance to Part 1 Validation. Promptly following designation of the Selected Targets, Fulcrum will (a) provide the JSC with the identity of all Selected Targets, (b) notify the JSC as to whether any Screened Targets that were considered for advancement to Part 1 Validation are Excluded Targets (which, in such case, pursuant to Section 3.6.8 (Excluded Target) such Screened Targets shall not be selected by the JSC as a Selected Target) and [**]. Following designation of the Selected Targets and the JSC decision as to which Selected Targets to advance forward, each Party will initiate and conduct the Part 1 Validation activities described in paragraph 5.2 and Figure 2 of the Research Plan that are assigned to such Party for each Selected Target for each Potential Project Gene, which for Fulcrum will include [**] (“Part 1 Validation”). For MyoKardia, Part 1 Validation activities include [**]. Within [**] after a Party’s completion of its Part 1 Validation activities, such Party will deliver a report containing all data resulting from such Part 1 Validation for all Selected Targets and for all Potential Project Genes to the JSC (each, a “Part 1 Validation Data Package”).
